Laboratory investigation of hypercoagulability

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 2, 1998, Pages 111-126

  Francis, John L ^a,b  

^a FLORIDA HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Activated protein C resistance; Antithrombin; Lupus anticoagulants; Protein C; Protein S; Risk factors; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; FIBRINOGEN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

BLEEDING TENDENCY; CLINICAL LABORATORY; CONFERENCE PAPER; GENE MUTATION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LABORATORY DIAGNOSIS; MOLECULAR GENETICS; PRIORITY JOURNAL; THROMBOPHILIA; THROMBOSIS;

EID: 0031916252     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995830     Document Type: Conference Paper

References (156)

1. Broze GJ. Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trend Cardiovasc Med 1992;2:72-77
2. Broze GJ, Gailani D. The role of factor XI in coagulation. Thromb Haemostas 1993;70:72-74
3. Roath S, Francis JL. Normal blood coagulation, fibrinolysis and natural inhibitors of coagulation. In: Uppington J (ed.). International Anesthiology Clinics. Coagulation Disorders and the Hemoglobinopathies. Boston: Little, Brown and Company: 1985:23-35
4. Heijboer H, Brandjes DPM, Büller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. N Engl J Med 1990;323:1512-1516
5. Preston FE, Briet E. Familial thrombosis. In: Brenner MK, Hoffbrand AV, eds. Recent Advances in Haematology. Edinburgh: Churchill Livingstone;1993:217-239
6. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characerized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008
7. Koster T, Rosendaal FR, de Ronde H, Briet E. Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506
8. Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinolysis 1994;5:51-57
9. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330: 517-522
10. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-1993
11. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994;94:923-927
12. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
13. Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation factor V Leiden mutation may have a racial background. Thromb Haemostas 1995;74:1381-1382
14. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-1730
15. Emmerich J, Alhenc-Gelas M, Gandrille S, Fiessinger JN, Aiach M. A new cause of familial hypercoagulable state: Activated protein C resistance. Presse Méd 1994;23:1285-1287
16. Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med 1995;237:221-227
17. Engel H, Zwang L, Van Vliet HHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemostas 1996;75:267-269
18. Zehnder JL, Benson RC. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol 1996;106:107-111
19. 506 allele. Thromb Haemostas 1995; 74:1380-1381 (Letter)
20. Jorquera JI, Aznar J, Fernández MA, Montoro JM, Curats R, Casaña P. A modification of the APC resistance test and its application to the study of patients on coumarin therapy. Thromb Res 1996;82:217-224
21. Meyer T, Garcia M, Helms E, Francis DA, Francis JL. Temporal changes in the activated protein C resistance ratio in a heterozygote for FV Leiden are abolished by dilution in FV-deficient plasma. Clin Appl Thromb Hemostas 1997;3:99-101
22. Martorell JR, Muñoz-Castillo A, Gil JL. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract. Thromb Haemostas 1995;74: 796-797
23. Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G. Acquired protein C dysfunction hut not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995;125:56-65
24. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995;85:1704-1711
25. Nicolaes GAF, Thomassen MCLGD, Van Oerle R, et al. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemostas 1996;76:404-410
26. Váradi K, Moritz B, Lang H, et al. A chromogenic assay for activated protein C resistance. Br J Haematol 1995;90:884-891
27. Hoagland LE, Triplett DA, Peng F, Barna L. APC-resistance as measured by a textarin time assay: Comparison to the APTT-based method. Thromb Res 1996;83:363-373
28. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia. Part 2. Thromb Haemostas 1996;76:824-834
29. Pedersen OD, Sidelmann J, Gram J, Jespersen J. Influence of blood handling on determination of plasma resistance against activated protein C. Fibrinolysis 1996;10:153-154
30. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemostas 1993;70:1067-1071
31. Cooper PC, Hampton KK, Makris M, Abuzenadah A, Paul B, Preston FE. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 1994;88:201-203
32. Koeleman BP, Reitsma PH, Allaart CF, Berlina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-1035
33. Koeleman BPC, Van Rumpt D, Hamulyák K, Reitsma PH, Bertina RM. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemostas 1995;74:580-583
34. 506 allele, and venous thrombosis. Ann Hematol 1996;72:166-176
35. Van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemostas 1996;75:417-421
36. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and Factor V Leiden -Effect on thrombosis. N Engl J Med 1996;334:763-768
37. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995;346:1593-1596
38. Bridey F, Wolf M, Laissy JP, Morin V, Lefebvre M, de Prost D. Fatal cerebral venous sinus thrombosis associated with the Factor V Leiden mutation and the use of oral contraceptives. Thromb Haemostas 1995;74:1382 (Letter)
39. Chaplain MAJ, Giles SM, Sleeman BD, Jarvis RJ. A mathematical analysis of a model for tumour angiogenesis. J Math Biol 1995;33:744-770
40. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the Factor V Arg 506 Gln mutation. Blood Coag Fibrinolysis 1995;6:245-248
41. 506-factor V. Thromb Res 1995;80:441-443
42. Van de Locht LTF, Kuypers AWHM, Verbruggen BW, Linssen PCM, Novakova IRO, Mensink EJBM. Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis. Thromb Haemostas 1995; 74:1276-1279
43. 506→Gln) causing protein C resistance. Thromh Res 1996;83:87-96
44. Voelkerding KV, Wu L, Williams EC, et al. Factor V R506Q gene mutation analysis by PCR-RFLP - optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Am J Clin Pathol 1996;106:100-106
45. Lane DA, Olds RR, Thein S-L. Antithrombin and its deficiency states. Blood Coag Fibrinolysis 1992;3:315-341
46. Barrowcliffe TW, Thomas DP. Antithrombin III and heparin. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1987:849-869
47. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromh Diath Haemorrh 1965;13:516-530
48. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemostas 1991:65:839 (Abst)
49. Lane DA, Ireland H, Olds RJ, Thein SL, Perry DJ, Aiach M. Antithrombin III: A database of mutations. Thromb Haemostas 1991;66:657-661
50. Bock SC, Marrian JA, Radziejewska E. Antithrombin III Utah: Proline 407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988;27:6171-6178
51. Sorum Y, Handeland GF, Abildgaard U. On the clinical significance of acquired antithrombin deficiency. Folia Haematol Int Mag Klin Morphol Blutforsch 1984;111:797-805
52. Hoffmann R. The thrombo-embolic risk in surgery. Hepatogastroenterology 1991;38:272-278
53. von Kaulla E, Droegemueller W, von Kaulla KN. Conjugated estrogens and hypercoagulabilily. Am J Obstet Gynecol 1975; 122:688-692
54. Ødegard OR, Abildgaard U. Antithrombin III: Critical review of assay methods. Significance of variations in health and disease. Haemostasis 1978;7:127-134
55. Esmon CT. The protein-C anticoagulant pathway. Arterioscler Thromb 1992;12:135-145
56. Walker FJ, Fay PJ. Regulation of blood coagulation by the protein-C system. FASEB J 1992;6:2561-2567
57. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1375
58. Bertina RM, Broekmans AW, Van der Linden IK, Mertens K. Potein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982;48:1-5
59. Mannucci PM, Owen WG. Basic and clinical aspects of proteins C and S. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1987:452-464
60. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemostas 1988;59:18-22
61. Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-995
62. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989;73:712-717
63. Bauer KA. Pathobiology of the hypercoagulable state: Clinical features, laboratory evaluation, and management. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds. Hematology. Basic Principles and Practice. New York: Churchill Livingstone; 1991:1415-1430
64. Reitsma PH. Protein C deficiency: Summary of the 1995 database update. Nucleic Acids Res 1996;24:157-159
65. Stern DM, Kaiser E, Nawroth PP. Regulation of the coagulation system by vascular endothelial cells. Haemostasis 1988;18: 202-214
66. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984;311:1525-1528
67. Schwartz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-1300
68. Moreb J, Kitchens CS. Acquired functional protein S deficiency, cerebral venous thrombosis and coumarin skin necrosis in association with antiphospholipid syndrome: Report of two cases. Am J Med 1989;87:207-210
69. Ploos van Amstel JK, van der Zanden AL, Bakker H, Reitsma PH, Bertina RM. Two genes homologous with protein S cDNA are located on chromosome 3. Thromb Haemostas 1987;58:982-987
70. Engesser L, Broeckmans AW, Briet E, Brummer EJP, Bertina RM. Hereditary protein S deficiency: Clinical manifestations. Ann Intern Med 1987;106:677-682
71. Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986;67:504-508
72. Faioni EM, Boyer-Neumann C, Franchi F, Wolf M, Meyer D, Mannucci PM. Another protein S functional assay is sensitive to resistance to activated protein C. Thromb Haemostas 1994;72:648 (Letter)
73. Viganó D'Angelo S, Mazzola G, Della Valle P, Testa S, Pattarini E, D'Angelo A. Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays. Thromb Res 1995;77:375-378
74. Ens GE. Spurious protein S deficiency as a result of elevated factor VII levels. Clin Hemost Rev 1995;9:18
75. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-translated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
76. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: Prevalence in a UK anticoagulant clinic population. Br J Haematol 1997;98:353-355
77. Hillarp A, Zoller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemostas 1997;78:990-992
78. Howard TE, Marusa M, Channell C, Duncan A. A patient homozygous for a mutation in the prothrombin gene 3′-untranslated region associated with massive thrombosis. Blood Coag Fibrinolysis 1997;8:316-319
79. Alhene-Gelas M, Le Cam-Duchez V, Emmerich J, et al. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families. Blood 1997;90:1711 (Letter)
80. Watzke HH, Schüttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res 1997;87:521-526
81. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-1750
82. Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemostas 1997;78:1157-1158
83. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997;96:15-18
84. Feinstein DI. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985;313:1348-1350
85. McNeil P, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid syndrome. Adv Immunol 1991;49:193-280
86. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for identification of lupus anticoagulants - on behalf of the subcommittee on lupus anticoagulants antiphospholipid antibodies of the ISTH. Thromb Haemostas 1995; 74:1597-1603
87. Clyne LP, White PF. Time dependency of lupuslike anticoagulants. Arch Intern Med 1988;148:1060-1063
88. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemostas 1995;74:1185-1190
89. Reyes H, Dearing L, Shoenfield Y, Peter JB. Antiphospholipid antibodies: A critique of their heterogeneity and hegemony. Semin Thromb Hemostas 1994;20:89-100
90. Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The working group on methodologies in haemostasis from the GEHT (groupe d'etudes sur l'hemostase et la thrombose). Thromb Haemostas 1995;73:444-452
91. Kuritzky L. Homocysteine as a risk factor for arteriosclerosis. Hosp Pract 1996;31:37-41
92. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41
93. Den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-885
94. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762
95. Quere I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene. N Engl J Med 1996;335:289 (Letter)
96. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-1782
97. Currie IC, Wilson YG, Scott J, et al. Homocysteine: An independent risk factor for the failure of vascular intervention. Br J Surg 1996;83:1238-1241
98. Irvine C, Wilson YG, Currie IC, et al. Hyperhomocysteinaemia is a risk factor for vein graft stenosis. Eur J Vasc Endovasc Surg 1996;12:304-309
99. Neugebauer S, Baba T, Kurokawa K, Watanabe T. Detective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 1997;349:473-474 (Letter)
100. Harpel PC. Homocysteine, atherogenesis and thrombosis. Fibrinolysis 1997;11:77-80
101. Bellamy MF, McDowell IFW. Putative mechanisms for vascular damage by homocysteine. J Inherited Metab Dis 1997;20: 307-315
102. D'Angelo A, Mazzola G, Crippa L, Fermo I, D'Angelo SV. Hyperhomocysteinemia and venous thromboembolic disease. Haematologica 1997;82:211-219
103. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q J Med 1997;90:519-524
104. Daskalakis I, Lucock MD, Anderson A, Wild J, Schorah CJ, Levene MI. Determination of plasma total homocysteine and cysteine using HPLC with fluorescence detection and an ammonium 7-fluoro-2, 1, 3-benzoxadiazole-4-sulphonate (sbd-f) derivatization protocol optimized for antioxidant concentration, derivatization reagent concentration, temperature and matrix ph. Biomed Chromatogr 1996;10:205-212
105. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMX analyzer. Clin Chem 1995;41:991-994
106. Tollefson DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981;68:589-594
107. Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985;ii:414-416
108. Tvan TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985;ii: 413-414
109. Betima RM, Van der Linden IK, Engesser L, Muller HP, Brommer EJP. Hereditary heparin cofactor II deficiency and the risk of development of venous thrombosis. Thromb Haemostas 1987;57:196-201
110. Schneider CL. The active principle of placental toxin: Thromboplastin; its inactivation in blood: Antithromboplastin. Am J Physiol 1947;149:123-129
111. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Milotich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988;71: 335-343
112. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393
113. Llobet D, Falkon L, Mateo J, et al. Low levels of tissue factor pathway inhibitor (TFPI) in two oui of three members of a family with thrombophilia. Thromb Res 1995;80:413-418
114. Sakariassen KS, Barstad RM. Mechanisms of thromboembolism at arterial plaques. Blood Coag Fibrinolysis 1993;4:615-625
115. Mammen EF. Congenital coagulation protein disorders. In: Bick RL, Bennett JM, Brynes RK, et al., eds. Hematology. Clinical and Laboratory Practice, St Louis: Mosby - Year Book Inc. 1993:1391-1420
116. Halbmayer WM, Mannhalter C, Feichtinger C, Ruhi K, Fischer M. Factor XII (Hageman factor) deficiency: A risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction. Wien Med Wochenschr 1993;143:43-50
117. Braulke I, Pruggmayer M, Melloh P, Hinney B, Köstering H, Gunther E. Factor XII (Hageman) deficiency in women with habitual abortion: New subpopulation of recurrent aborters? Fertil Steril 1993;59:98-101
118. Halbmayer WM, Haushofer A, Schön R, et al. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: Evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemostas 1994;71:68-72
119. Winter M, Gallimore M, Jones DW. Should factor XII assays be included in thrombophilia screening? Lancet 1995;346:52 (Letter)
120. Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hugeman's factor and deep-vein thrombosis: Leiden Thrombophilia Study. Br J Haematol 1994;87:422-424
121. Castaman G, Ruggeri M, Tosetto A, Missiaglia E, Rodeghiero F. Thrombosis in patients with heterozygous and homozygous factor XII deficiency is not explained by the associated presence of factor V Leiden. Thromb Haemostas 1996;76:275 (Letter)
122. Shigekiyo T, Uno Y, Tomonari A, Satoh K, Hondo H, Ueda S, Saito S. Type I congenital plasminogen deficiency is not a risk factor for thrombosis. Thromb Haemostas 1992;67:189-192
123. Tait RC, Walker ID, Conkie JA, Islam SIAM, McCall F. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thromb Haemostas 1996;76:1004-1008
124. Züger M, Biasiutti FD, Furlan M, Mannhalter C, Lämmle B. Plasminogen deficiency: An additional risk factor for thrombosis in a family with factor V R506Q mutation? Thromb Haemostas 1996;76:475-476
125. Mammen EF. Ten years' experience with the "sticky platelet syndrome." Clin Appl Thromb Hemostas 1995;1:66-72
126. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel de Paris. The New Sydenham Society, London 1865; 3:94-96
127. Sun NCJ, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10-16
128. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993;117:71-77
129. Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996;87:4925-4936
130. Boisclair MD, Philippou H, Lane DA. Thrombogenic mechanisms in the human: Fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coag Fibrinolysis 1993;4:1007-1021
131. von Kaulla KN, Ostendorf P, von Kaulla E. The impedance machine: A new bedside coagulation recording device. J Med 1975;6:73-87
132. Helt DA, Walker D, Pilkingston SN, Smith DC. Sonoclot analysis. Br J Anaesth 1995;75:771-776
133. Peck SD. Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test. Thromb Haemostas 1979;42:764-777
134. Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulabilily in patients with cancer using the Sonoclot analyzer and thromboelastography. Thromb Res 1994;74: 335-346
135. Spiess BD, Tuman KJ, McCarthy RJ, Delaria GA, Schillo R, Ivanovich AD. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monitoring 1986;3:25-30
136. Kang YG, Martin DJ, Marquez J. et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985;64:888-896
137. Howland WS, Castro EB, Fortner JB, Gould P. Hypercoagulability. Thrombelastographic monitoring during extensive hepatic surgery. Arch Surg 1974;108:605-608
138. Cohen E, Caprini J, Zuckerman L, Vagher P, Robinson B. Evaluation of three methods used to identify accelerated coagulability. Thromb Res 1977;10:587-604
139. Franz RC, Coetzee WJ. The thrombelastographic diagnosis of hemostatic defects. Surg Annu 1981;13:75-107
140. Arcelus JI, Traverso CI, Caprini JA. Thromboelastography for the assessment of hypercoagulability during general surgery. Semin Thromb Hemostas 1995;21 (suppl):21-26
141. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Invest 1981;98:917-928
142. Rivers RPA, Cattermole HEJ, Wright I. The expression of surface tissue factor apoprotein by blood monocytes in the course of infections in early infancy. Pediatr Res 1992;31: 567-573
143. Lattanzio A, Montemurro P, Pannarale O, et al. Increased production of procoagulant activity (tissue factor) by human peripheral-blood monocytes after intralipid infusion. Clin Nutr 1984;3:177-181
144. Edwards RL, Levine JB, Green R, et al. Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocytc tissue factor activity. Gastroenterology 1987;42:329-337
145. Neri Serneri GG, Abbate R, Gensini GF, Gori AM, Attanasio M, Martini F. Monocyte activation and increased procoagulant activity in unstable angina. Lancet 1990;336:1444-1445
146. Ternisien C, Ollivier V, Chollelmartin S, Deprost D. Increased monocyte procoagulant activity in patients with systemic lupus erythematosus. Nouv Rev Fr Hématol 1990;32:373-375
147. Kappelmayer J, Bernabei A, Edmunds LH Jr., Edgington TS, Colman RW. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993;72:1075-1081
148. Edwards RL, Rickles FR. The role of leukocytes in the activalion of blood coagulation. Semin Hematol 1992;29:202-212
149. Bilan M, Mohsen M, Levi E, et al. Structural requirements forinhibition of melanoma lung colonization by heparanase inhibiting species of heparin. Isr J Med Sci 1995;31:106-118
150. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-1332
151. Reverter JC, Tàssies D, Font J, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996;16: 1319-1326
152. Carson SD. Continuous chromogenic tissue factor activity assay: Comparison to clot-based assays and sensitivity established using pure tissue factor. Thromb Res 1987;47:379-387
153. Luther T, Flossel C, Hietschhold V, Koslowski R, Müller M. Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytes - comparison to procoagulant activity of mononuclear blood cells. Blut 1990;61:375-378
154. Muller AD, van Dam-Mieras MCE, Hemker HC. Measurement of macrophage cellular procoagulant activity. Haemostasis 1985;15:108-113
155. Helin HJ, Fox RI, Edgington TS. The instructor cell for the human procoagulant monocyte response to bacterial lipopolysaccharide is a Leu-3a+ T cell by fluorescence-activated cell sorting. J Immunol 1983;131:749-752
156. Amirkhosravi A, Alexander M, May K, et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemostas 1996;75:87-95